Log In
Print
BCIQ
Print
Print this Print this
 

gevokizumab (S 78989, XOMA 052)

Also known as: formerly XMA005.2

  Manage Alerts
Collapse Summary General Information
Company Xoma Corp.
DescriptionHumanized IgG2 mAb against IL-1 beta
Molecular Target Interleukin-1 (IL-1) beta
Mechanism of ActionInterleukin-1 (IL-1) inhibitor; Antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$885.0M

$15.0M

$800.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today